Merit Medical Systems demonstrated solid earnings growth in fiscal 2025, driven by its diversified cardiovascular and endoscopy product segments. The October 2025 CEO transition from founder Fred Lampropoulos to Martha Aronson introduces an important strategic inflection point, with the company emphasizing continuity amid competitive and regulatory pressures. Strong operating cash flow generation enabled increased capital investment, supporting product innovation to maintain market differentiation. Regulatory compliance and evolving reimbursement environments remain the chief external challenges impacting long-term growth prospects.